Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Endocrine ; 73(1): 125-130, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-33439464

RESUMO

AIM: Radioiodine therapy (RIT) may trigger the development of Graves' ophthalmopathy (GO) or exacerbate pre-existing subclinical GO. Therefore, glucocorticoid administration is recommended for patients with pre-existing GO. Aim of this study was to analyze the influence of glucocorticoid therapy with methylprednisolone on intratherapeutic effective half-life (EHL) of radioiodine-131 in patients with Graves' disease (GD) as recent studies showed an effect for prednisolone. METHODS: In a retrospective study, 264 patients with GD who underwent RIT without any additional antithyroid medication were evaluated. Intrathyroidal EHL was determined pre- and intratherapeutically. Patients with co-existing GO (n = 43) received methylprednisolone according to a fixed scheme starting 1 day prior to RIT, patients without GO (n = 221) did not receive any protective glucocorticoid medication. The ratios of EHL during RIT and during radioiodine uptake test (RIUT) were compared. RESULTS: Patients receiving methylprednisolone showed a slight decrease of the mean EHL from 5.63 d (RIUT) to 5.39 d (RIT) (p > 0.05). A comparable result was obtained in patients without glucocorticoids (5.71 d (RIUT) to 5.47 d (RIT); p > 0.05). The ratios of the EHL between RIT and RIUT failed to show a significant difference between the two groups. EHL is therefore not significantly influenced by an additional protective treatment with methylprednisolone. CONCLUSIONS: In the present study a decreased intrathyroidal EHL under glucocorticoid medication with methylprednisolone could not be detected. Therefore, co-medication with methylprednisolone in patients with GO may be preferred to avoid an intratherapeutic decrease of EHL by accompanying protective glucocorticoides.


Assuntos
Doença de Graves , Radioisótopos do Iodo , Doença de Graves/tratamento farmacológico , Doença de Graves/radioterapia , Meia-Vida , Humanos , Radioisótopos do Iodo/uso terapêutico , Metilprednisolona/uso terapêutico , Estudos Retrospectivos
2.
Ann Chir ; 45(7): 566-9, 1991.
Artigo em Inglês | MEDLINE | ID: mdl-1755621

RESUMO

Between 1982 and 1989 hospitalized treatment was applied to 615 patients aged between 85 and 101 years. The average age was 88.8 years. Operations were performed on 406 of them (66.1%). The surgical lethality amounted 16.5%. The lethality in conjunction with emergency operation was as high as 30.8% or as low as 10.7% in the context of elective operations. X-ray findings recorded from heart and lung as well as ECG provided reliable criteria for assessment of the surgical risk.


Assuntos
Arteriopatias Oclusivas/cirurgia , Fraturas do Fêmur/cirurgia , Neoplasias Gastrointestinais/cirurgia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Apendicite/mortalidade , Apendicite/cirurgia , Arteriopatias Oclusivas/mortalidade , Feminino , Fraturas do Fêmur/mortalidade , Neoplasias Gastrointestinais/mortalidade , Hérnia/mortalidade , Herniorrafia , Humanos , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA